GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

European shares ended Wednesday's choppy session higher, as a rise in healthcare companies GSK and Novo Nordisk following ...

UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold ...

The FTSE 100 rose by 0.6%, propelled by surges in GSK and gold mining shares, as market focus shifted toward the Bank of ...

Wall Street was mostly lower on Wednesday despite US employment growth picking up last month by more than expected.

Match Group (MTCH) shares declined when the online dating service provider removed its CEO and provided soft guidance as sales at Tinder and other units fell. Concerns about a trade war with China ...

--On pace for largest percent increase since Dec. 6, 2022, when it rose 7.85% --Down 51.37% from its all-time closing high of $76.92 on Jan. 6, 1999 ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

The biggest fallers on the FTSE 100 were Diageo, down 92.5p to 2235p, DCC, down 195p to 5300p, Croda, down 103p to 3110p, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...